Nasal Spray Flu Vaccine Approved by FDA for Home Administration

First Influenza Vaccine That Does Not Need to be Administered by a Health Care Provider

HI INDIA NEWS DESK
WASHNGTON, DC- The U.S. Food and Drug Administration (FDA) has approved FluMist for self- or caregiver-administration, broadening access to the nasal spray flu vaccine. FluMist is designed to prevent influenza caused by virus subtypes A and B in individuals aged 2 through 49. Initially approved in 2003 for people aged 5 to 49, its usage was expanded in 2007 to include children aged 2 to 5. FluMist is notable as the first flu vaccine that doesn’t require administration by a healthcare provider.

FluMist contains a weakened live influenza virus and is administered via a nasal spray. While still requiring a prescription, the vaccine can now be administered by either a healthcare provider or a caregiver aged 18 or older. For self-administration, the vaccine will be available through third-party online pharmacies, where customers will undergo screening and eligibility assessments before receiving the vaccine.

FluMist’s common side effects include fever in young children, and runny nose or nasal congestion in both children and adults. To ensure safety and effectiveness, a study was conducted on the ease of use of FluMist by vaccine recipients and caregivers.

This FDA approval was granted to MedImmune LLC, expanding the convenience and accessibility of flu prevention during the annual flu season, which affects millions and can lead to severe complications or death, particularly among vulnerable populations.